POMDOCTOR Ltd (NASDAQ: POM) Stock Competitors & Peer Comparison
See POM's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for POM and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| POM | $0.87 | +7.35% | 5.9M | -0.17 | -$5.03 | N/A |
| RPRX | $56.77 | -0.86% | 25.2B | 10.81 | $5.25 | +1.60% |
| CORT | $110.77 | +2.61% | 12B | 316.49 | $0.35 | N/A |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| LQDA | $90.22 | +0.89% | 8B | 644.43 | $0.14 | N/A |
| KNSA | $76.06 | -0.59% | 5.8B | 84.51 | $0.90 | N/A |
| TRLV | $8.75 | -2.78% | 1.5B | -20.83 | -$0.42 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| CUVL | $6.68 | -0.65% | 336.6M | N/A | N/A | N/A |
Stock Comparison
Royalty Pharma plc (NASDAQ: RPRX)
POM vs RPRX Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, RPRX has a market cap of 25.2B. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while RPRX trades at $56.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas RPRX's P/E ratio is 10.81. In terms of profitability, POM's ROE is +0.16%, compared to RPRX's ROE of +0.11%. Regarding short-term risk, POM is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for POM.Check RPRX's competition here
Corcept Therapeutics Incorporated (NASDAQ: CORT)
POM vs CORT Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, CORT has a market cap of 12B. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while CORT trades at $110.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas CORT's P/E ratio is 316.49. In terms of profitability, POM's ROE is +0.16%, compared to CORT's ROE of +0.08%. Regarding short-term risk, POM is more volatile compared to CORT. This indicates higher risk in terms of short-term price fluctuations for POM.Check CORT's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
POM vs WBA Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas WBA's P/E ratio is -1.64. In terms of profitability, POM's ROE is +0.16%, compared to WBA's ROE of -0.42%. Regarding short-term risk, POM is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for POM.Check WBA's competition here
Liquidia Corporation (NASDAQ: LQDA)
POM vs LQDA Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, LQDA has a market cap of 8B. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while LQDA trades at $90.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas LQDA's P/E ratio is 644.43. In terms of profitability, POM's ROE is +0.16%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, POM is more volatile compared to LQDA. This indicates higher risk in terms of short-term price fluctuations for POM.Check LQDA's competition here
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA)
POM vs KNSA Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, KNSA has a market cap of 5.8B. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while KNSA trades at $76.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas KNSA's P/E ratio is 84.51. In terms of profitability, POM's ROE is +0.16%, compared to KNSA's ROE of +0.14%. Regarding short-term risk, POM is more volatile compared to KNSA. This indicates higher risk in terms of short-term price fluctuations for POM.Check KNSA's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
POM vs TRLV Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, TRLV has a market cap of 1.5B. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while TRLV trades at $8.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas TRLV's P/E ratio is -20.83. In terms of profitability, POM's ROE is +0.16%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, POM is more volatile compared to TRLV. This indicates higher risk in terms of short-term price fluctuations for POM.Check TRLV's competition here
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL)
POM vs HROWL Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas HROWL's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.16%, compared to HROWL's ROE of -0.34%. Regarding short-term risk, POM is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for POM.Check HROWL's competition here
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM)
POM vs HROWM Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas HROWM's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.16%, compared to HROWM's ROE of -0.34%. Regarding short-term risk, POM is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for POM.Check HROWM's competition here
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL)
POM vs CUVL Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, CUVL has a market cap of 336.6M. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while CUVL trades at $6.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas CUVL's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.16%, compared to CUVL's ROE of N/A. Regarding short-term risk, POM is more volatile compared to CUVL. This indicates higher risk in terms of short-term price fluctuations for POM.Check CUVL's competition here
LifeMD, Inc. (NASDAQ: LFMD)
POM vs LFMD Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, LFMD has a market cap of 172.2M. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while LFMD trades at $3.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas LFMD's P/E ratio is -7.12. In terms of profitability, POM's ROE is +0.16%, compared to LFMD's ROE of -1.79%. Regarding short-term risk, POM is more volatile compared to LFMD. This indicates higher risk in terms of short-term price fluctuations for POM.Check LFMD's competition here
LifeMD, Inc. (NASDAQ: LFMDP)
POM vs LFMDP Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, LFMDP has a market cap of 160M. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while LFMDP trades at $23.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas LFMDP's P/E ratio is -722.96. In terms of profitability, POM's ROE is +0.16%, compared to LFMDP's ROE of -1.79%. Regarding short-term risk, POM is more volatile compared to LFMDP. This indicates higher risk in terms of short-term price fluctuations for POM.Check LFMDP's competition here
Circle8 Group, Inc. (NASDAQ: CIRC)
POM vs CIRC Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, CIRC has a market cap of 65.1M. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while CIRC trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas CIRC's P/E ratio is -1.64. In terms of profitability, POM's ROE is +0.16%, compared to CIRC's ROE of +0.00%. Regarding short-term risk, POM is more volatile compared to CIRC. This indicates higher risk in terms of short-term price fluctuations for POM.Check CIRC's competition here
Rite Aid Corporation (NYSE: RAD)
POM vs RAD Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas RAD's P/E ratio is -0.05. In terms of profitability, POM's ROE is +0.16%, compared to RAD's ROE of +2.76%. Regarding short-term risk, POM is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for POM.Check RAD's competition here
Damora Therapeutics, Inc. (NASDAQ: GLTO)
POM vs GLTO Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas GLTO's P/E ratio is -1.78. In terms of profitability, POM's ROE is +0.16%, compared to GLTO's ROE of -1.22%. Regarding short-term risk, POM is more volatile compared to GLTO. This indicates higher risk in terms of short-term price fluctuations for POM.Check GLTO's competition here
SCYNEXIS, Inc. (NASDAQ: SCYX)
POM vs SCYX Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, SCYX has a market cap of 33M. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while SCYX trades at $5.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas SCYX's P/E ratio is -1.53. In terms of profitability, POM's ROE is +0.16%, compared to SCYX's ROE of -0.57%. Regarding short-term risk, POM is more volatile compared to SCYX. This indicates higher risk in terms of short-term price fluctuations for POM.Check SCYX's competition here
Nasus Pharma Ltd. (AMEX: NSRX)
POM vs NSRX Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, NSRX has a market cap of 29.8M. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while NSRX trades at $3.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas NSRX's P/E ratio is -4.80. In terms of profitability, POM's ROE is +0.16%, compared to NSRX's ROE of +0.00%. Regarding short-term risk, POM is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for POM.Check NSRX's competition here
Stablecoin Development Corp. (AMEX: SDEV)
POM vs SDEV Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, SDEV has a market cap of 28.2M. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while SDEV trades at $1.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas SDEV's P/E ratio is -0.18. In terms of profitability, POM's ROE is +0.16%, compared to SDEV's ROE of +7.90%. Regarding short-term risk, POM is more volatile compared to SDEV. This indicates higher risk in terms of short-term price fluctuations for POM.Check SDEV's competition here
Biofrontera Inc. (NASDAQ: BFRI)
POM vs BFRI Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, BFRI has a market cap of 16.3M. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while BFRI trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas BFRI's P/E ratio is -1.19. In terms of profitability, POM's ROE is +0.16%, compared to BFRI's ROE of -4.77%. Regarding short-term risk, POM is more volatile compared to BFRI. This indicates higher risk in terms of short-term price fluctuations for POM.Check BFRI's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
POM vs CJJD Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas CJJD's P/E ratio is -0.46. In terms of profitability, POM's ROE is +0.16%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, POM is more volatile compared to CJJD. This indicates higher risk in terms of short-term price fluctuations for POM.Check CJJD's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
POM vs SSY Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas SSY's P/E ratio is -2.86. In terms of profitability, POM's ROE is +0.16%, compared to SSY's ROE of -0.09%. Regarding short-term risk, POM is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for POM.Check SSY's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
POM vs PAVS Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, PAVS has a market cap of 5.3M. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while PAVS trades at $6.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas PAVS's P/E ratio is -0.07. In terms of profitability, POM's ROE is +0.16%, compared to PAVS's ROE of -0.27%. Regarding short-term risk, POM is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for POM.Check PAVS's competition here
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD)
POM vs HKPD Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, HKPD has a market cap of 4.6M. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while HKPD trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas HKPD's P/E ratio is -7.01. In terms of profitability, POM's ROE is +0.16%, compared to HKPD's ROE of -0.14%. Regarding short-term risk, POM is more volatile compared to HKPD. This indicates higher risk in terms of short-term price fluctuations for POM.Check HKPD's competition here
AIxCrypto Holdings, Inc. (NASDAQ: AIXC)
POM vs AIXC Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, AIXC has a market cap of 4.3M. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while AIXC trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas AIXC's P/E ratio is -0.09. In terms of profitability, POM's ROE is +0.16%, compared to AIXC's ROE of -0.94%. Regarding short-term risk, POM is less volatile compared to AIXC. This indicates lower risk in terms of short-term price fluctuations for POM.Check AIXC's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
POM vs MDVL Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas MDVL's P/E ratio is -0.05. In terms of profitability, POM's ROE is +0.16%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, POM is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for POM.Check MDVL's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
POM vs ATNFW Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas ATNFW's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.16%, compared to ATNFW's ROE of -2.41%. Regarding short-term risk, POM is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for POM.Check ATNFW's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
POM vs BGMSP Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, POM's ROE is +0.16%, compared to BGMSP's ROE of -0.51%. Regarding short-term risk, POM is more volatile compared to BGMSP. This indicates higher risk in terms of short-term price fluctuations for POM.Check BGMSP's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
POM vs BGMS Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, BGMS has a market cap of 2M. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while BGMS trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas BGMS's P/E ratio is -0.26. In terms of profitability, POM's ROE is +0.16%, compared to BGMS's ROE of -0.51%. Regarding short-term risk, POM is more volatile compared to BGMS. This indicates higher risk in terms of short-term price fluctuations for POM.Check BGMS's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
POM vs AZNH Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas AZNH's P/E ratio is 38.35. In terms of profitability, POM's ROE is +0.16%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, POM is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for POM.Check AZNH's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
POM vs LFLYW Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, POM's ROE is +0.16%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, POM is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for POM.Check LFLYW's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFMW)
POM vs SBFMW Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, SBFMW has a market cap of 175.2K. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while SBFMW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas SBFMW's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.16%, compared to SBFMW's ROE of -0.26%. Regarding short-term risk, POM is less volatile compared to SBFMW. This indicates lower risk in terms of short-term price fluctuations for POM.Check SBFMW's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
POM vs ESRX Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas ESRX's P/E ratio is 10.69. In terms of profitability, POM's ROE is +0.16%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, POM is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for POM.Check ESRX's competition here
POZEN Inc. (NASDAQ: POZN)
POM vs POZN Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, POZN has a market cap of 0. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas POZN's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.16%, compared to POZN's ROE of +0.61%. Regarding short-term risk, POM is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for POM.Check POZN's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
POM vs OREX Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, OREX has a market cap of 0. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas OREX's P/E ratio is -0.14. In terms of profitability, POM's ROE is +0.16%, compared to OREX's ROE of -0.54%. Regarding short-term risk, POM is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for POM.Check OREX's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
POM vs IPXL Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas IPXL's P/E ratio is -10.11. In terms of profitability, POM's ROE is +0.16%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, POM is more volatile compared to IPXL. This indicates higher risk in terms of short-term price fluctuations for POM.Check IPXL's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
POM vs CPD Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, CPD has a market cap of 0. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas CPD's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.16%, compared to CPD's ROE of N/A. Regarding short-term risk, POM is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for POM.Check CPD's competition here
Shire plc (NASDAQ: SHPG)
POM vs SHPG Comparison August 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 5.9M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, POM is priced at $0.87 on the NASDAQ, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.17, whereas SHPG's P/E ratio is 11.35. In terms of profitability, POM's ROE is +0.16%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, POM is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for POM.Check SHPG's competition here